Axiom Bio
Founded 2024 · 25 employees on LinkedIn · 6 known investors
Find your way into Axiom Bio
Axi.om uses agentic intelligence and AI to predict, explain, and fix drug toxicity early in development by leveraging the largest experimental-to-clinical dataset of profiled molecules linked to human clinical outcomes.
Investors · 6
Abstract VenturesSan Francisco · $250K – $750K
Amplify PartnersMenlo Park · $500K – $5M
CRV (Charles River Ventures)Bay Area · $250K – $5M
Inception Studio CapitalSilicon Valley · $100K – $1.5M
Atria VenturesreportedSan Francisco · $500K – $3Mvia Chris Leiter · inferred
Dimension CapitalreportedSan Francisco · $1M – $10M
Founder mafia
2 people who came through Axiom Bio went on to found or lead other companies.
Competitors · 3
by search overlap
Numerion Labs13 shared keywordsNumerion combines drug discovery expertise with machine learning and computational chemistry. The company applies AI to drug development.
Axiom Therapeutics12 shared keywordsAxiom Therapeutics runs a drug discovery platform for covalent inhibitors, applying machine learning to speed up physics-based simulations. The work is aimed at oncology research teams pursuing targets that have been difficult to drug.
Axiom9 shared keywordsAxiom is a fully managed, petabyte-scale event store and observability platform that ingests schema-less, high-cardinality event data and lets teams query it using its piped query language (APL). It targets engineering teams handling large log and telemetry volumes, positioned as an alternative to Splunk and Datadog, with native support for AI-agent querying.
Companies competing with Axiom Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Top 8 Proprietary Trading Firms & Best Forex Prop Firms / Axiaxi.com · Jul 2026Frequently asked questions
- What does Axiom Bio do?
- Axi.om uses agentic intelligence and AI to predict, explain, and fix drug toxicity early in development by leveraging the largest experimental-to-clinical dataset of profiled molecules linked to human clinical outcomes.
- Who are Axiom Bio's investors?
- Axiom Bio's investors include Abstract Ventures, Amplify Partners, CRV (Charles River Ventures), Inception Studio Capital, Atria Ventures, Dimension Capital.